Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F3UTU
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $50,261
Award facts
- Contract value 100% obligated
- $50,260.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $50,260.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 30, 2026, for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injections. This is a non-set-aside competitive award with a completion date of February 2, 2026, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a task order executed under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has demonstrated significant capability in fulfilling federal medical procurement requirements through open competition. The company's extensive contract history with DLA encompasses delivery of diverse pharmaceutical products across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies to support military treatment facilities and veterans' healthcare programs. This award for Dupixent—a biologic immunosuppressant used primarily for treating moderate-to-severe atopic dermatitis and eosinophilic conditions—reflects the company's continued role as a critical vendor for federal military healthcare systems.
Quick answers
Who was awarded contract SPE2DR26F3UTU?
SPE2DR26F3UTU was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26F3UTU worth?
The government has obligated $50,261 on SPE2DR26F3UTU.
Is contract SPE2DR26F3UTU an order under another contract?
Yes. SPE2DR26F3UTU is a delivery order under SPE2DR25D2104, an indefinite delivery contract.
Was contract SPE2DR26F3UTU competed?
The extent of competition for SPE2DR26F3UTU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award